ClinicalTrials.gg
TerminatedNCT05421013isSCCUpdated Oct 7, 2026Results posted

Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC

A Phase 1/2 interventional study of STP705 in Facial isSCC, sponsored by Sirnaomics. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Sirnaomics · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The Sponsor terminated the study at the conclusion of Cohort A. Cohort B and Cohort C were not initiated. The Sponsor terminated the study before reaching the planned 30 subjects for corporate strategic reasons not related to safety.
Updated Oct 7, 2026Now TerminatedResults posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Open label, dose escalation to evaluate safety.

Read the detailed description

Evaluate safety, tolerability, and efficacy of various doses of STP705 administered as intralesional injection in subjects with facial isSCC.

There will be 3 cohorts of 10 subjects each. Enrolled subjects will receive STP705 once weekly for 6 weeks. The lesion will be excised 60 days after.

02

Conditions studied

  • Facial isSCC
03

In context

Lead sponsor

Sirnaomics is the lead sponsor of 13 studies on the registry; 1 is open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 2 (22%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Inclusion Criteria: Subjects are required to meet all of the following criteria for enrollment into the study:

  1. Male or female adult ≥ 18 years of age.
  2. Primary, confirmed facial isSCC lesion suitable for excision with a minimum diameter of 0.5 cm and with a maximum diameter of 2.0 cm.
  3. Histological diagnosis of a qualified isSCC skin lesion (evidenced by a confirmatory histopathology report) made no more than 6 months prior to the screening visit.
  4. No other dermatological disease in the isSCC target lesion or surrounding area, which in the opinion of the investigator, could interfere with the study.
  5. Willing to refrain from using non-approved lotions or creams on the target lesion and surrounding area during the treatment period (sunscreen and moisturizers allowed).
  6. Willing to refrain from exposure to excessive direct sunlight or ultraviolet light and to avoid the use of tanning parlors for the duration of the study.
  7. Laboratory values for the tests (listed in the Study Schedule) within the reference ranges as defined by the local laboratory, or "out of range" test results that are clinically acceptable to the investigator.
  8. Ability to follow study instructions and likely to complete all study requirements.
  9. Written obtained, including consent for tissue to be examined and stored by the Central Histology Lab.
  10. Written consent to allow photographs of the target isSCC lesion to be used as part of the study data and documentation.
  11. For female subjects of , a negative pregnancy test at screening and using an acceptable form of (oral / implantable / injectable / transdermal contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous relationship with a partner who has had a vasectomy at least 6 months prior to screening).

Exclusion criteria

EXCLUSION CRITERIA

  1. Pregnant, lactating, or planning to become pregnant.
  2. Presence of known or suspected systemic cancer.
  3. Confirmatory histological report of the qualified isSCC lesion reveals evidence of severe squamous metaplasia, infiltrative, desmoplastic or micronodular growth patterns in the opinion of the investigator.
  4. History of recurrence of the target isSCC lesion.
  5. Concurrent disease or treatment that suppresses the immune system.
  6. Subjects with baseline corrected interval QTc > 480 msec using Fridericia's formula.
  7. Chronic medical condition that in the judgment of the investigator(s) would interfere with the performance of the study or would place the patient at undue risk.
  8. Known sensitivity to any of the ingredients in the study medication including an allergy to trehalose.
  9. Use of a tanning bed or other excessive or prolonged exposure to ultraviolet light or direct sunlight during the study.
  10. Treatment with systemic chemotherapeutic agents within the 6 months prior to the screening visit.
  11. Use of systemic retinoids within the 6 months prior to the screening period.
  12. Treatment with systemic immunomodulators or within the 6 months prior to the screening period.
  13. Use of topical immunomodulators within 2 cm of the target isSCC lesion within the 4 weeks prior to the screening period.
  14. Treatment with the following topical agents within 2 cm of the target isSCC lesion within the 4 weeks prior to the screening visit: aminolevulinic acid, 5-fluorouracil, , retinoids, diclofenac, ingenol mebutate, tirbanibulin, or imiquimod.
  15. Treatment with liquid nitrogen, surgical excision, or curettage within 2 cm of the target isSCC lesion during the 4 weeks prior to the screening visit.
  16. Evidence of current chronic alcohol or drug abuse that, in the opinion of the investigator, would impair the subject's ability to comply with study schedule.
  17. Current enrollment in an drug or device study or participation in such a study within 4 weeks of the screening visit.
  18. In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions and requirements of the protocol and complete the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    STP705 30ug

    STP705 will be administered once weekly for 6 weeks

    Drug: STP705

  • Experimental
    STP705 60ug

    STP705 will be administered once weekly for 6 weeks

    Drug: STP705

  • Experimental
    STP705 90ug

    STP705 will be administered once weekly for 6 weeks

    Drug: STP705

Interventions

  • DrugSTP705

    STP705 targets TGFB-1 and COX-2 mRNA respectively.

    Also known as: STP705 Powder for Injection

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With Histological Clerance of Treated isSCC Lesion at the End of Treatment

    Histological clearance will be defined as the absence of detectable evidence of isSCC tumor cell nests determined by pathology review

    Time frame: 21 weeks

Secondary outcomes

  1. Change in Size of the Treated isSCC Lesion Over the Pre-excision Treatment Period.

    A Baseline assessment of lesion size was made by the investigator at T1 (first treatment visit). This was measured by widest width and longest length using a caliper or a ruler as deemed by the investigator's judgement. The change in size was assessed every visit until the surgical excision of isSCC at the EOT Visit.

    Time frame: 21 weeks

07

Results

Posted Oct 7, 2026

Participant flow

Participant flow — Overall Study
MilestoneSTP705 30ugSTP705 60ugSTP705 90ug
Started900
Completed800
Not completed100
Withdrew: Withdrawal by subject100

Outcome measures

PrimaryProportion of Participants With Histological Clerance of Treated isSCC Lesion at the End of Treatment

Histological clearance will be defined as the absence of detectable evidence of isSCC tumor cell nests determined by pathology review

Time frame:
21 weeks
Reported as:
Count of participants · Participants
Proportion of Participants With Histological Clerance of Treated isSCC Lesion at the End of Treatment
ParticipantsSTP705 30ugSTP705 60ugSTP705 90ug
Proportion of Participants With Histological Clerance of Treated isSCC Lesion at the End of Treatment600
SecondaryChange in Size of the Treated isSCC Lesion Over the Pre-excision Treatment Period.

A Baseline assessment of lesion size was made by the investigator at T1 (first treatment visit). This was measured by widest width and longest length using a caliper or a ruler as deemed by the investigator's judgement. The change in size was assessed every visit until the surgical excision of isSCC at the EOT Visit.

Time frame:
21 weeks
Reported as:
Mean · millimeters squared (mm2)
Change in Size of the Treated isSCC Lesion Over the Pre-excision Treatment Period.
millimeters squared (mm2)STP705 30ugSTP705 60ugSTP705 90ug
Change in Size of the Treated isSCC Lesion Over the Pre-excision Treatment Period.11.4 (0 to 37)——

Adverse events

Collected over for example, "from enrollment until end of follow-up, up to 18 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
STP705 30ug0/9 (0%)0/9 (0%)5/9 (55.6%)
STP705 60ug———
STP705 90ug———
Most frequent other events
Most frequent other events
EventSTP705 30ugSTP705 60ugSTP705 90ug
Injection site indurationGeneral disorders2/9——
Vision blurredEye disorders1/9——
Urinary tract infectionInfections and infestations1/9——
Injection site painGeneral disorders1/9——

Baseline characteristics

The Sponsor terminated the study at the conclusion of Cohort A. Cohort B and Cohort C were not initiated. The Sponsor terminated the study before reaching the planned 30 subjects for corporate strategic reasons not related to safety.

Age, Categorical
Age, Categorical(Participants)STP705 30ugSTP705 60ugSTP705 90ugTotal
<=18 years0000
Between 18 and 65 years1001
>=65 years8008
Age, Continuous
Age, Continuous(years)STP705 30ugSTP705 60ugSTP705 90ugTotal
Median70 (53 to 89)——70 (53 to 89)
Sex: Female, Male
Sex: Female, Male(Participants)STP705 30ugSTP705 60ugSTP705 90ugTotal
Female2002
Male7007
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)STP705 30ugSTP705 60ugSTP705 90ugTotal
Hispanic or Latino1001
Not Hispanic or Latino8008
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)STP705 30ugSTP705 60ugSTP705 90ugTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White9009
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)STP705 30ugSTP705 60ugSTP705 90ugTotal
United States9——9
Facial isSCC lesion
Facial isSCC lesion(Participants)STP705 30ugSTP705 60ugSTP705 90ugTotal
Count of participants9009
08

Study locations

1 site
  • Center for Clinical and Cosmetic Research
    Aventura, Florida 33180, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Mar 2023, 7 months.

Results were first posted in Oct 2026, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2022
First posted
Jun 16, 2022
StartActual
Aug 1, 2022
Primary completionActual
Mar 29, 2023
CompletionActual
Mar 29, 2023
Results first posted
Oct 7, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Terminated The Sponsor terminated the study at the conclusion of Cohort A. Cohort B and Cohort C were not initiated. The Sponsor terminated the study before reaching the planned 30 subjects for corporate strategic reasons not related to safety.
changed Oct 7, 2026
Results
Results posted
posted Oct 7, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedProportion of participants with histological cleranceParticipants With Histological Clerance of treatedTreated isSCC lesionLesion at the endEnd of treatmentTreatmentTime frame: 21 weeks
Oct 7, 2026
Documents
Secondary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)Now Change in Size of the Treated isSCC Lesion Over the Pre-excision Treatment Period.Time frame: 21 weeks
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Completed→Terminated
    Why stopped The Sponsor terminated the study at the conclusion of Cohort A. Cohort B and Cohort C were not initiated. The Sponsor terminated the study before reaching the planned 30 subjects for corporate strategic reasons not related to safety.
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedProportion of participants with histological cleranceParticipants With Histological Clerance of treatedTreated isSCC lesionLesion at the endEnd of treatmentTreatmentTime frame: 21 weeks
    Secondary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)Now Change in Size of the Treated isSCC Lesion Over the Pre-excision Treatment Period.Time frame: 21 weeks
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05421013
Lead sponsor
Sirnaomics
Responsible party
Sponsor
First posted
Jun 16, 2022
Start date
Aug 1, 2022
Primary completion
Mar 29, 2023
Completion
Mar 29, 2023
Results posted
Oct 7, 2026
Last update
Oct 7, 2026

Study contacts

Mark Nestor, MD
principal investigator · Center for Clinical and Cosmetic Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cotsiranib

Start the discussion